Savara Inc

SVRA remains in a Stage 2 advancing uptrend marked by a clear higher-high/higher-low sequence, underpinning a bullish medium-term bias. After peaking in early July, price has pulled back into the rising 50-day MA and the 200-day MA confluence, with short EMAs sloping lower and short-term momentum deteriorating. Without a Lockout Rally override, execution timing is unfavorable now and should be deferred, stalking for a pullback acceptance at key support. Overall, maintain medium-term bullish stance while waiting for supportive price action around the 50-DMA zone.

• ↑FDA accepted MOLBREEVI BLA with PDUFA set for Nov 22 2026.
• ↑IMPALA-2 trial enrollment completes mid-2026; topline data in H1 2027.
• ↓No Q1 2026 revenue; net loss of $0.15/share vs -$0.1374 est.